Concepedia

Toru Kodo

TK

6

Publications

188

Citations

6

H-Index

1994

Active since

Affiliations

Sumitomo Dainippon Pharma (Japan)(Current)

Toru Kodo is an author at Sumitomo Dainippon Pharma (Japan) specializing in neuropharmacology, pharmacology, and drug discovery.

Top concepts

MedicineBiochemistryPharmacologyDrug DiscoveryNeuropharmacologyPharmacotherapyNatural SciencesMedicinal ChemistryNeurochemistryChemical Biology

Publications per year

1994–2022

6

Publications

6

Tricyclic Quinoxalinediones: 5,6-Dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-Dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as Potent Antagonists for the Glycine Binding Site of the NMDA Receptor

Ryu Nagata, Norihiko Tanno, Toru Kodo et al. · Journal of Medicinal Chemistry · 1994 · 71 citations

Combinatorial Chemistry, Pharmacotherapy, Heterocycle Chemistry +19

Design, synthesis and structure–activity relationships of novel benzoxazolone derivatives as 18 kDa translocator protein (TSPO) ligands

Takayuki Fukaya, Toru Kodo, Takeo Ishiyama et al. · Bioorganic & Medicinal Chemistry · 2012 · 32 citations · Full text

Structure-activity relationships of tricyclic quinoxalinediones as potent antagonists for the glycine binding site of the NMDA receptor 2

Ryu Nagata, Toru Kodo, Hiroshi Yamaguchi et al. · Bioorganic & Medicinal Chemistry Letters · 1995 · 27 citations

Nmda Receptor 2, Biochemistry, Functional Selectivity +8

Tricyclic Indole-2-carboxylic Acids: Highly in Vivo Active and Selective Antagonists for the Glycine Binding Site of the NMDA Receptor

Seiji Katayama, Nobuyuki Ae, Toru Kodo et al. · Journal of Medicinal Chemistry · 2003 · 25 citations · Full text

Nmda-glycine Binding Site, Pharmacotherapy, Pharmaceutical Chemistry +18

Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer

Sadanori Watanabe, Akitada Yogo, Tsuguteru Otsubo et al. · BMC Cancer · 2022 · 20 citations · Full text

Rows per page

1–5 of 6